Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AMG 337 |
| Synonyms | |
| Therapy Description |
AMG 337 selectively inhibits c-MET and may induce cell death in tumors overexpressing c-MET or expressing constitutively activated c-MET (PMID: 30366938). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AMG 337 | AMG337|AMG-337 | MET Inhibitor 59 | AMG 337 selectively inhibits c-MET and may induce cell death in tumors overexpressing c-MET or expressing constitutively activated c-MET (PMID: 30366938). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03147976 | Phase II | AMG 337 | QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors | Withdrawn | USA | 0 |
| NCT02016534 | Phase II | AMG 337 | Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors | Terminated | USA | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUT | AUS | 4 |
| NCT03132155 | Phase II | AMG 337 | QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma | Terminated | USA | 0 |
| NCT01253707 | Phase I | AMG 337 | A Study of AMG 337 in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
| NCT02344810 | Phase Ib/II | AMG 337 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer | Withdrawn | USA | 0 |